drugset

drugset / Trial / NCT03515980

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

NCT03515980 ↗

Phase 1 Completed 76 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an investigational study of experimental Medication BMS-986231 given to participants with weakened or damaged liver function.

Timeline

Start: 2018-05-25
Primary completion: 2019-08-29
Completion: 2019-08-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cimlanod	Other / unclassified	—	Intravenous

Indications